
    
      This is an uncontrolled extension study open only to patients who completed the Phase II/III
      core study 12011.201 and volunteered to continue or to cross-over to L-CsA inhalation
      therapy.

      Determination of long-term safety and efficacy outcome over a maximum of three years will be
      assessed.
    
  